Communiqués Vaxart, Inc.

Actions

VXRT

US92243A2006

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:59:12 04/09/2026			Varia. 5j.	Varia. 1 janv.
0,4950 ^USD	+0,51%		-1,33%	+42,90%

26/08	Vaxart obtient un nouveau brevet européen pour sa technologie de vaccin oral contre le norovirus	MT
25/08	Vaxart, Inc. annonce la création d'un comité des affaires cliniques et réglementaires et d'un comité d'engagement des actionnaires	CI

Communiqués

26/08	Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology	AQ
07/08	Vaxart : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results	AQ
30/07	Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET	AQ
21/07	Vaxart to Participate in BTIG Biotechnology Conference 2026	AQ
17/07	Vaxart Announces Results of Annual Meeting of Stockholders	AQ
06/07	Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine	AQ
01/07	Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements	AQ
26/06	Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY	AQ
25/06	Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial	AQ
16/06	Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting	AQ
15/06	Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum	AQ
09/06	Vaxart to Participate in BTIG Infectious Disease Day 2026	AQ
08/06	Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY	AQ
01/06	Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders	AQ
19/05	Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders	AQ
08/05	Vaxart : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results	AQ
01/05	Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET	AQ
23/04	Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors	AQ
17/04	Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital	AQ
13/03	Vaxart : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU
12/03	Vaxart Provides Business Update and Reports Full Year 2025 Financial Results	AQ
03/03	Vaxart to Host Upcoming Conference Calls	AQ
18/02	Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026	AQ